Company / Cost of Revenue
Kiniksa Pharmaceuticals International, plc Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$77.7M
FY2025
5-year range
$9.1M / $77.7M
FY2021-FY2025
Trend
+27.5%
vs FY2024
Sector context
#47 of 85
Health Care
What the data says
At $78M, Kiniksa Pharmaceuticals International, plc's cost of revenue ranks #39 of 85 in the Health Care sector. Cost of Revenue has increased for 4 consecutive years, from $9M in FY2021 to $78M in FY2025.
Based on SEC 10-K filings.
$78M in FY2025 with a 3-year CAGR of +50.3%.
Increased from $33M to $78M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +50.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#39 of 85 in Health CareTop 45% of 85This company $77.7M Sector average $2.0B
▼
-96.1% below sector average
Key checks
Key Insights
- Kiniksa Pharmaceuticals International, plc's cost of revenue has grown for 4 consecutive years.
- 3-year CAGR of +50.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 27.5% year-over-year.
- Ranks #47 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.7M | +27.5% |
| FY2024 | $60.9M | +82.3% |
| FY2023 | $33.4M | +45.9% |
| FY2022 | $22.9M | +151.6% |
| FY2021 | $9.1M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026